SCHEMBL15569217

SCHEMBL15569217

CN[C@@H](C)C(=O)N[C@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)O)C(C)C

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
XIAP P98170 16/20 0.61
ACE P12821 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3728963 1.00 XIAP (0.61) XIAPACE
SCHEMBL4394017 0.91 XIAP (0.56) XIAPACE
SCHEMBL3726378 0.88 XIAP (0.58) XIAP
SCHEMBL3722425 0.86 XIAP (0.56) XIAP
SCHEMBL4394011 0.85 XIAP (0.60) XIAP
SCHEMBL7806754 0.84 ACE (0.59) ACE
SCHEMBL15605818 0.83 XIAP (0.74) XIAP
SCHEMBL16930761 0.83 XIAP (0.74) XIAP
SCHEMBL3725956 0.82 XIAP (0.47) XIAP
SCHEMBL16464915 0.82 XIAP (0.82) XIAPACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422332-B2 Azaheterocycles as BIR2 and/or BIR3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-08-23 US disclosed
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS HOFFMANN-LA ROCHE INC. 2015-07-30 US disclosed
EP-2885275-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
WO-2014026882-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS BIRC3, BIRC5, BIRC2 XIAP 4/4885ACE 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.